Kizzmekia Corbett Biography, Age, Height, Husband, Net Worth, Family

April 2024 · 6 minute read

Age, Biography and Wiki

Kizzmekia Corbett (Kizzmekia Shanta Corbett) was born on 26 January, 1986 in Hurdle Mills, North Carolina, United States, is an American immunologist. Discover Kizzmekia Corbett's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is She in this year and how She spends money? Also learn how She earned most of networth at the age of 37 years old?

Popular AsKizzmekia Shanta Corbett
OccupationImmunologist
Age37 years old
Zodiac SignAquarius
Born26 January, 1986
Birthday26 January
BirthplaceHurdle Mills, North Carolina, U.S.
NationalityAmerican

We recommend you to check the complete list of Famous People born on 26 January. She is a member of famous with the age 37 years old group.

Kizzmekia Corbett Height, Weight & Measurements

At 37 years old, Kizzmekia Corbett height not available right now. We will update Kizzmekia Corbett's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
HeightNot Available
WeightNot Available
Body MeasurementsNot Available
Eye ColorNot Available
Hair ColorNot Available

Dating & Relationship status

She is currently single. She is not dating anyone. We don't have much information about She's past relationship and any previous engaged. According to our Database, She has no children.

Family
ParentsNot Available
HusbandNot Available
SiblingNot Available
ChildrenNot Available

Kizzmekia Corbett Net Worth

Her net worth has been growing significantly in 2022-2023. So, how much is Kizzmekia Corbett worth at the age of 37 years old? Kizzmekia Corbett’s income source is mostly from being a successful . She is from American. We have estimated Kizzmekia Corbett's net worth , money, salary, income, and assets.

Net Worth in 2023$1 Million - $5 Million
Salary in 2023Under Review
Net Worth in 2022Pending
Salary in 2022Under Review
HouseNot Available
CarsNot Available
Source of Income

Kizzmekia Corbett Social Network

Timeline

To manufacture and test the COVID-19 vaccine Corbett's team partnered with Moderna, a biotechnology company, to rapidly enter animal studies. Subsequently, the vaccine entered Phase 1 clinical trial only 66 days after the virus sequence was released. The trial, to be completed in at least 45 people, is a dose escalation study in the form of two injections separated by 28 days. Corbett's work afforded her the opportunity to be a part of the National Institutes of Health team that welcomed Donald Trump to the Dale and Betty Bumpers Vaccine Research Center in March 2020.

Corbett went to Oak Lane Elementary School and A.L. Stanback Middle School. Her fourth grade teacher, Myrtis Bradsher, recalls recognizing Corbett's talent at an early age and encouraging Kizzy's mother to place her in advanced classes. "I always thought she is going to do something one day. She dotted i’s and crossed t’s. The best in my 30 years of teaching," Bradsher said in a 2020 interview with The Washington Post.

While in high school, Corbett realized that she wanted to pursue a scientific career, and as part of a program called ProjectSEED, spent her summer holiday working in research laboratories, one of which was at UNC’s Kenan Labs with organic chemist James Morkin. In 2005, she was a summer intern at SUNY StonyBrook in Gloria Viboud's lab where she studied Yersinia pseudotuberculosis pathogenesis. From 2006 to 2007, she worked as a lab tech in Susan Dorsey's lab at the University of Maryland School of Nursing.

At the onset of the COVID-19 pandemic, Corbett started working on a vaccine to protect people from coronavirus disease. Recognizing that the virus was similar to severe acute respiratory syndrome coronavirus, Corbett's team utilized previous knowledge of optimal coronavirus S proteins to tackle the novel coronavirus. S proteins form a “crown” on the surface of coronaviruses and are crucial for engagement of host cell receptors and the initiation of membrane fusion in coronavirus disease. This makes them a particularly vulnerable target for coronavirus prophylactics and therapeutics. Based on her previous research, Corbett's team, in collaboration with investigators at UT Austin, transplanted stabilizing mutations from SARS-CoV S protein into SARS-CoV-2 spike protein. She was part of the NIH team who helped solve the cryogenic electron microscopy (CryoEM) structure of the SARS-CoV-2 spike protein. Her prior research suggested that messenger RNA (mRNA) encoding S protein could be used to excite the immune response to produce protective antibodies against coronavirus disease 2019.

In October 2014, Corbett became a research fellow, working as a viral immunologist, at the NIH. Her research aims to uncover mechanisms of viral pathogenesis and host immunity. She specifically focuses on development of novel vaccines for coronaviridae. Her early research considered the development of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) vaccine antigens. During this time, she identified a simple way to make spike proteins that are stabilized in a conformation that renders them more immunogenic and manufacturable, in collaboration with researchers at Scripps Research Institute and Dartmouth College.

From 2009 to 2014, Corbett studied human antibody responses to dengue virus in Sri Lankan children under the supervision of Aravinda de Silva at University of North Carolina at Chapel Hill. She studied how people produce antibodies in response to dengue fever, and how the genetics of dengue fever impact the severity of a disease. From April to May 2014, as part of her research for her dissertation, Corbett worked as a visiting scholar at Genetech Research Institute in Colombo, Sri Lanka.

After earning her bachelor's degree, from 2006 to 2009, Corbett was a biological sciences trainer at the National Institutes of Health (NIH), where she worked alongside Dr. Barney Graham. At the NIH, Corbett worked on the pathogenesis of respiratory syncytial virus pathogenesis as well as on a project focused on innovative vaccine platform advancement.

In 2004, Corbett graduated from Orange High School in Hillsborough, North Carolina. In 2008, Corbett received a B.S. in biological sciences and sociology from the University of Maryland, Baltimore County (UMBC), as a student in the Meyerhoff Scholars Program. In 2014, Corbett received a PhD in microbiology and immunology from the University of North Carolina at Chapel Hill.

Kizzmekia "Kizzy" Shanta Corbett (born January 26, 1986) is an American viral immunologist at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID NIH) based in Bethesda, Maryland. Appointed to the VRC in 2014, she is currently the scientific lead of the VRC's Coronavirus Team, with research efforts aimed at propelling novel coronavirus vaccines, including a COVID-19 vaccine.

ncG1vNJzZmivp6x7pLHLnpmsmZeaxKq3yGeaqKVfoLa7xsyeoqKZXZi8s67Eras%3D